Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Sleep Wake Disorders 1Radiation Injuries 1Pinealoma 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1Meningioma 1Medulloblastoma 1Gliosarcoma 1Glioma, Subependymal 1Glioma 1Glioblastoma 1Fatigue 1Ependymoma 1Depression 1Craniopharyngioma 1Cognition Disorders 1Chronic Pain 1Choroid Plexus Neoplasms 1Central Nervous System Neoplasms 1Breast Neoplasms 1Brain Neoplasms 1Astrocytoma 1Anxiety Disorders 1

Interventions

Psilocybin 5Psychotherapy 2Fluoxetine 2Cannabidiol 2nabiximols 1Yoga 1Therapeutics 1Sertraline 1Self-Management 1Selective Serotonin Reuptake Inhibitors 1Professional Autonomy 1Pharmaceutical Preparations 1Niacin 1Neoadjuvant Therapy 1N-Methyl-3,4-methylenedioxyamphetamine 1Minocycline 1Medical Marijuana 1Ketamine 1Injections 1Hormones 1Gemcitabine 1Exercise 1Dronabinol 1Donepezil 1Clomipramine 1Citalopram 1Cisplatin 1Aromatherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Anxiety Disorders × Donepezil × Clear all
NCT01466270 2021-10-20

Study of Donepezil in Female Breast Cancer Survivors With Cognitive Dysfunction

Wake Forest University Health Sciences

Phase 2 Completed
62 enrolled 12 charts
Breast

Anxiety Disorders, Breast Neoplasms, Cognition Disorders, Depression, Fatigue, Sleep Wake Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡